How often do we see companies with growth like this in the last two years??
CRYO-CELL's Monthly U-Cord(TM) Stem Cell Preservation Sales Highest In Company's History
CLEARWATER, Fla., Sept. 5 /PRNewswire/ -- Wanda D. Dearth, President and Chief Operating Officer of CRYO-CELL International, Inc. (Nasdaq: CCEL), announced today that the Company concluded its fiscal third quarter by achieving its ninth consecutive record month for sales of its umbilical cord blood (U-Cord)(TM) preservation program.
(Photo: newscom.com
Highlights for August 2001 include:
* Client enrollments increased more than 25% over July with almost 2,000 collection kits being sold. The Company processed more than 1,500 cord blood samples during August, representing a 20% increase over July.
* August sales from the U-Cord(TM) program were $540,370, representing a 21% increase over July 2001 sales and a 163% increase over August 2000 sales of $205,172.
* Fiscal 3rd quarter 2001 sales of $1,414,442 compare to FY 2000 3rd quarter sales of $554,628, a 155% increase.
* Year to date sales are $4,046,931 compared to $1,500,269 for the same nine-month period during 2000, representing a 170% year-to-year increase. YTD 2001 revenues include $750,000 from the sale of a Revenue Sharing Agreement during May; discounting this impact, YTD sales from the U-Cord program increased 120% on a year-to-year basis.
Ms. Dearth commented, "The strong sales results during August have positioned the Company well for a profitable third quarter and we are pleased with the momentum the business is carrying into the fourth quarter." CRYO-CELL will timely file its third quarter report by October 15, 2001.
According to Daniel Richard, Chairman and Chief Executive Officer of CRYO-CELL, the above sales do not include "Other Income" from the Company's international license fees from Europe, Mexico/Central America and Israel/Middle East. In addition to these fees, the Company is currently receiving on-going entitlements from the operations of CRYO-CELL Europe. These entitlements will be received and also reported as other income during the third quarter 2001."
CRYO-CELL is America's fastest growing and largest exclusive, private U-Cord stem cell preservation firm. The Company pioneered affordable cord blood stem cell storage. Its initial fees are 1/4 to 1/5 the cost of many of its major competitors, and its $50 annual fee is fixed for specimens already in storage. CRYO-CELL's high quality and affordability are a few of the reasons why approximately 17,250 OB/GYNs and medical caregivers have supported their patients' decisions to preserve their newborns' U-Cord stem cells in the CRYO-CELL program.
CRYO-CELL is a publicly traded company (Nasdaq: CCEL).
CRYO-CELL Web site: www.cryo-cell.com.
Forward-Looking Statement
Statements wherein the terms "believes," "intends," "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward looking statements or paragraphs. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE CRYO-CELL International, Inc.
CO: CRYO-CELL International, Inc.
ST: Florida
IN: MTC BIO OTC
SU:
09/05/2001 09:07 EDT prnewswire.com |
